Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy

How to Cite

OrthoEvidence. Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy. ACE Report. 2013;2(3):12. Available from: https://myorthoevidene.com/AceReport/Report/4343

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma

Cancer. 2012 Dec 1;118(23):5888-93

Contributing Authors: NM Bernthal N Federman FR Eilber SD Nelson JJ Eckardt FC Eilber WD Tap

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...